Stock Analiz

Rein Therapeutics, Inc. RNTX

Biotechnology: Pharmaceutical Preparations · IPO 2017 · data as of November 13, 2026

$0.55Market cap $48M
Open the interactive analysis →

Rein Therapeutics, Inc. (RNTX) is a healthcare company listed in the US with a market value of about $48M.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -102%.

About Rein Therapeutics

Rein Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2017. It was profitable in 0 of the last 10 years in our data. Its share count rose by 461% over three years (dilution for shareholders).

Score: 0.8 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B0.9
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)—
ROIC (5-yr avg.)-101.8%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue$0$0$0$0$0$0$0$0$0$0
Net income-$50M-$63M-$16M-$27M-$26M-$27M-$29M-$32M-$23M-$18M
Free cash flow————-$24M-$20M-$27M-$32M-$21M—
EPS (diluted)$-1.96$-3.51$-3.42$-6.02$-5.89$-0.61$-1.20$-2.14$-3.04$-42.35
Net margin——————————
ROIC-236.4%-94.6%-13.1%-117.0%-47.7%-133.1%-112.3%-100.8%-38.0%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Rein Therapeutics pay a dividend?

Not currently.

Is Rein Therapeutics a good stock to buy?

We do not give buy or sell advice. Rein Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.